Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date

BCOP Clinical Sessions: Lung Cancer Therapy and Molecular Targets

Conference Correspondent  - Conference Correspondent, ASHP

A presentation on lung cancer therapy and molecular targets was given by Gary Jean, PharmD, BCOP, Clements University Hospital in Dallas, TX, and Christine M. Walko, PharmD, BCOP,  DeBartolo Family Personalized Medicine Institute at the Moffitt Cancer Center in Tampa, FL, at this year’s ASHP meeting.

In 2016, it was estimated that there will be more than 220,000 new cases of non–small-cell lung cancer (NSCLC); it is the second most common cancer among men and women.1 NSCLC is the leading cause of cancer-related death, and approximately 50% of patients present with metastatic disease.1 Treatment for NSCLC often is driven by histology and testing for driver mutations. Dr. Jean highlighted one study that found that in more than 1000 patients with metastatic adenocarcinoma lung cancer, approximately 64% were identified to have oncogenic driver mutations. In 28% of those patients, these results were used to select a targeted therapy or clinical trial.2

Mutations are common in NSCLC, and the emergence of targeted therapy in the early 2000s has changed the treatment landscape for NSCLC and the emergence of numerous new therapies. Dr. Jean stated that although targeted therapy has shown great improvement in patients through the years, oftentimes the reliability of the response is not always certain.

Dr. Walko focused on how the mutation landscape often changes for a patient over time and the need for NSCLC treatment to evolve, especially through the practice of precision medicine. The goal of precision medicine is to determine the optimal treatment or sequence of treatments for a patient.  Through the course of highlighting patient cases, Dr. Walko emphasized the importance of precision medicine not only in selecting therapy but by testing a tumor’s genome and how you can potentially predict the response to a particular therapy as well as other diagnostic and prognostic data.

Lastly, Dr. Walko closed by highlighting the importance of translating the data you receive from a tumor genome test into viable clinical recommendations by ensuring that all available data are included; the interactions of all the mutations present and the unique patient characteristics are all considered when making a clinical decision. She also highlighted the importance of clinical trial opportunities and eventually being able to translate these insights to the average oncologist to improve care for patients overall.

Jean G, Walko CM. Clinical session presentation at ASHP Midyear Clinical Meeting. Las Vegas, NV; December 2016.

  1. American Cancer Society. Cancer Facts & Figures 2016. Atlanta, GA: American Cancer Society; 2016.
  2. Kris MG, et al. JAMA. 2014;311:1998-2006.
Related Items
Sexual Dysfunction After Cancer: Why Aren’t We Talking About It?
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in Conference Correspondent, ONS
The Importance of Compassion: Perspective From a Lifelong Patient
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in Conference Correspondent, ONS
Using a Team Approach to Tackle Opioid Abuse in Patients with Cancer
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in Conference Correspondent, ONS
Addressing the Second Victim Phenomenon
Charles Bankhead
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in Conference Correspondent, ONS
Palliative Care Use Dismal Among Patients with Hematologic Malignancies
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ASH, Palliative Care, Hematologic Cancers
Oral Multiple Myeloma Medication Linked to Decreased Productivity Loss
Chase Doyle
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ASH, Multiple Myeloma
Ivosidenib, New IDH1 Inhibitor, Elicits Complete Response in Relapsed Acute Myeloid Leukemia
Wayne Kuznar
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Drug Updates, ASH
“Superhero” Navigators Convene at the 8th Annual Navigation & Survivorship Conference
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in AONN+ News, Conference Correspondent
Silent Patients Find Their Voices Through an Advocate’s Journey
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Patient Advocacy, Conference Correspondent, ESMO
Measuring Financial Well-Being in Cancer Survivorship
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Survivorship
Last modified: February 20, 2019